New biopsy after antibiotic treatment: effect on outcomes of assisted reproduction in patients with infertility and chronic endometritis

Does Oral Antibiotic Therapy for Chronic Endometritis Improve Reproductive Outcomes in Assisted Reproductive Technology? A Prospective Cohort Study

“…11 The estimated prevalence of CE varied due to differences in the diagnostic criteria used in various studies. In the general population, the prevalence is between 0.8 and 19%, 12 in the infertile population; the prevalence is between 3 and 44%, 13 in infertile women with unexplained recurrent miscarriage, it ranges from 8.9 to 56.1% 14 and in women with repeated implantation failures prevalence ranges from 14 to 57%. 14 Currently, there are no well-established guidelines or consensus proposed for diagnosing CE.…”

Challenges in Clinical Diagnosis and Management of Chronic Endometritis

“…Some studies claim that re-examination for histopathologic CE following first-line doxycycline treatment is clinically insignificant in improving reproductive outcomes in infertile women undergoing assisted reproductive technology treatment [ 92 ]; however, a growing number of studies demonstrate that antibiotic treatment may improve the reproductive outcomes of infertile women with a history of RIF in subsequent IVF-ET cycles only if the cure of histopathologic CE is confirmed in the endometrial biopsy/IHC-CD138 afterward [ 20 ]. Otherwise, no sufficient evidence has been shown for improvements in reproductive outcomes in RIF women with persistent CE.…”

Bridging the Diagnostic Gap between Histopathologic and Hysteroscopic Chronic Endometritis with Deep Learning Models

“…CE is attracting interest because of its association with female infertility, including unexplained etiology (10–57%) [ 9 , 10 , 11 ], endometriosis (5–53%) [ 12 , 13 , 14 , 15 , 16 ], repeated implantation failure in an in vitro fertilization–embryo transfer program (7–31%) [ 7 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ], unexplained recurrent pregnancy loss (9–13%) [ 27 , 28 , 29 , 30 , 31 , 32 ], fallopian tubal infertility (45.9% of hydrosalpinx, 14.3% of peritubal adhesion, and 13.0% of tubal occlusion) [ 33 , 34 , 35 , 36 ], polycystic ovarian syndrome (32–42%) [ 37 ], endometrial polyps (86%) [ 38 , 39 , 40 , 41 , 42 , 43 ], submucosal uterine fibroids (69%) [ 44 ], septate uterus (46%) [ 44 ], intrauterine adhesion/Asherman syndrome (28–79%) [ 44 , 45 , 46 , 47 ], and cesarean scar disorder (28–66%) [ 48 , 49 ]. The European Society of Human Reproduction and Embryology Working Group recently published Good Practice Recommendations on Recurrent Implantation Failure 2023, a document in which assessment for CE can be considered for infertile women suffering from repeated implantation failure following in vitro fertilization–embryo transfer programs and tre...…”

“…CE is attracting interest because of its association with female infertility, including unexplained etiology (10-57%) [9][10][11], endometriosis (5-53%) [12][13][14][15][16], repeated implantation failure in an in vitro fertilization-embryo transfer program (7-31%) [7,[17][18][19][20][21][22][23][24][25][26], unexplained recurrent pregnancy loss (9-13%) [27][28][29][30][31][32], fallopian tubal infertility (45.9% of hydrosalpinx, 14.3% of peritubal adhesion, and 13.0% of tubal occlusion) [33][34][35][36], polycystic ovarian syndrome (32-42%) [37], endometrial polyps (86%) [38][39][40][41][42][43], submucosal uterine fibroids (69%) [44], septate uterus (46%) [44], intrauterine adhesion/Asherman syndrome (28-79%) [44][45][46][47], and cesarean scar disorder (28-66%) [48,49]. The European Society of Human Reproduction and Embryology Working Group recently published Good Practice Recommendations on R...…”